Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Clinician Scientist - Phase 1

McGill University

$187,500.00

Development of Enzyme Replacement Therapy for Urea Cycle Defects

FY 2008-09

Summary
Urea cycle defects (UCDs) are frequent genetic disorders, affecting up to 1/8200 children, and are notably difficult to treat, causing severe neurologic disease and early death. Novel therapies are urgently needed. Gene therapy is promising, but issues limiting its use include the difficulty in obtaining a sustained correction, and the immune reactions limiting re-administration of the vectors. An interesting therapeutic avenue is enzyme replacement therapy (ERT), which has permitted great advances in the treatment of lysosomal storage diseases (other genetic diseases). To apply such a therapy to UCDs, the intravenously injected enzyme should reach the interior of liver cells. This can be done by modifying the enzyme (adding a portion called a protein transduction domain, which will permit efficient cell entry) and injecting this enzyme intravenously. We hypothesize that protein transduction domains can be fused to urea cycle enzymes to develop enzyme replacement therapy for common urea cycle defects. The proof of principle will be done in mouse models. To develop ERT, we will first modify genes to encode the missing enzymes fused to the protein transduction domains. The fusion proteins will be produced in bacteria. We will verify the ability of the fusion proteins to reach the cytoplasm or mitochondria in vitro and in vivo in mice. We will assess correction of the disease by analysis of amino acids and other metabolites in the plasma and urine. We will also use a stable nitrogen isotope to study metabolic flux through the urea cycle in the mice. If we attain our goal in mice (i.e. correction of the disease), this will open the door to safe and effective therapies for UCDs in humans.
Program
CIHR Clinician Scientist - Phase 1
Location
Texas, United States of America
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
173692
Name
Campeau Philippe M
Region
Texas; Québec
Country
United States of America; Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Clinician Scientist
Projecttitle
Development of Enzyme Replacement Therapy for Urea Cycle Defects
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$187,500
Cihrequipment2
$0
Programname2
CIHR Clinician Scientist - Phase 1
Keyworddelim
Enzyme Replacement Therapy; Genetic Disorders; Inborn Errors Of Metabolism; Protein Transduction; Urea Cycle Defects
Abstract
Urea cycle defects (UCDs) are frequent genetic disorders, affecting up to 1/8200 children, and are notably difficult to treat, causing severe neurologic disease and early death. Novel therapies are urgently needed. Gene therapy is promising, but issues limiting its use include the difficulty in obtaining a sustained correction, and the immune reactions limiting re-administration of the vectors. An interesting therapeutic avenue is enzyme replacement therapy (ERT), which has permitted great advances in the treatment of lysosomal storage diseases (other genetic diseases). To apply such a therapy to UCDs, the intravenously injected enzyme should reach the interior of liver cells. This can be done by modifying the enzyme (adding a portion called a protein transduction domain, which will permit efficient cell entry) and injecting this enzyme intravenously. We hypothesize that protein transduction domains can be fused to urea cycle enzymes to develop enzyme replacement therapy for common urea cycle defects. The proof of principle will be done in mouse models. To develop ERT, we will first modify genes to encode the missing enzymes fused to the protein transduction domains. The fusion proteins will be produced in bacteria. We will verify the ability of the fusion proteins to reach the cytoplasm or mitochondria in vitro and in vivo in mice. We will assess correction of the disease by analysis of amino acids and other metabolites in the plasma and urine. We will also use a stable nitrogen isotope to study metabolic flux through the urea cycle in the mice. If we attain our goal in mice (i.e. correction of the disease), this will open the door to safe and effective therapies for UCDs in humans.
Competitiondate
200809
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Campeau, Philippe M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $187,500~ $0~